A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05651932. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT05651932
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- K36 Therapeutics, Inc.
- Industry
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Interventions
- Cohort A1 & A2: KTX-1001 Drug
- Cohort B1 & B2: KTX-1001+Mezigdomide Drug
- Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) Drug
- Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2023
- Primary completion
- Dec 30, 2027
- Completion
- Jun 29, 2028
- Last update posted
- Feb 9, 2026
2023 – 2028
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic | San Francisco | California | 94143 | Recruiting |
| Mayo Clinic Hospital - Florida | Jacksonville | Florida | 32224 | Recruiting |
| The Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Mayo Clinic - Transplant Center - Rochester | Rochester | Minnesota | 55905 | Recruiting |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Atrium Health, Levine Cancer Institute | Charlotte | North Carolina | 28204 | Recruiting |
| Duke University Hospital | Durham | North Carolina | 27705 | Recruiting |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center | Dallas | Texas | 75235 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05651932, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05651932 live on ClinicalTrials.gov.